113 related articles for article (PubMed ID: 27109950)
1. Anemia and Immunosuppressive Regimen in Renal Transplanted Patients: Single-Center Retrospective Study.
Carta P; Bigazzi B; Buti E; Antognoli G; Di Maria L; Caroti L; Minetti EE
Transplant Proc; 2016 Mar; 48(2):337-9. PubMed ID: 27109950
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
3. Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial.
Krishnan A; Teixeira-Pinto A; Chan D; Chakera A; Dogra G; Boudville N; Irish A; Morgan K; Phillips J; Wong G; Lim WH
Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28662279
[TBL] [Abstract][Full Text] [Related]
4. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
5. Anemia in kidney transplants without erythropoietic agents: levels of erythropoietin and iron parameters.
Florit EA; Hadad F; Rodriguez Cubillo B; De la Flor JC; Valga F; Perez Flores I; Calvo Romero N; Valero San Cecilio R; Barrientos Guzman A; Sanchez Fructuoso A
Transplant Proc; 2012 Nov; 44(9):2590-2. PubMed ID: 23146464
[TBL] [Abstract][Full Text] [Related]
6. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
8. Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study.
García-Bello JA; Romo-Del Río EG; Mendoza-Gómez E; Camarena-Arias PA; Santos-Caballero M
Transplant Proc; 2016 Mar; 48(2):639-42. PubMed ID: 27110020
[TBL] [Abstract][Full Text] [Related]
9. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
[TBL] [Abstract][Full Text] [Related]
10. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
11. Interstitial Lung Disease After Kidney Transplantation and the Role of Everolimus.
Solazzo A; Botta C; Nava F; Baisi A; Bonucchi D; Cappelli G
Transplant Proc; 2016 Mar; 48(2):349-51. PubMed ID: 27109953
[TBL] [Abstract][Full Text] [Related]
12. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience.
Boffini M; Sansone F; Patanè F; Bonato R; Ribezzo M; Iacovino C; Comoglio C; Rinaldi M
Transplant Proc; 2009 May; 41(4):1349-52. PubMed ID: 19460557
[TBL] [Abstract][Full Text] [Related]
13. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.
Moscarelli L; Caroti L; Antognoli G; Zanazzi M; Di Maria L; Carta P; Minetti E
Clin Transplant; 2013; 27(4):546-54. PubMed ID: 23758330
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
15. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine versus everolimus: effects on the glomerulus.
Baas MC; Kers J; Florquin S; de Fijter JW; van der Heide JJ; van den Bergh Weerman MA; ten Berge IJ; Bemelman FJ
Clin Transplant; 2013; 27(4):535-40. PubMed ID: 23795805
[TBL] [Abstract][Full Text] [Related]
17. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
[TBL] [Abstract][Full Text] [Related]
18. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
19. Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.
Sommerer C; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Wolters HH; Suwelack B; Klehr HU; Hauser IA; Stangl M; Nadalin S; Dürr M; Porstner M; May C; Wimmer P; Witzke O; Lehner F
Clin Nephrol; 2016 Apr; 85(4):215-25. PubMed ID: 26932178
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients.
Brunkhorst LC; Fichtner A; Höcker B; Burmeister G; Ahlenstiel-Grunow T; Krupka K; Bald M; Zapf A; Tönshoff B; Pape L
PLoS One; 2015; 10(9):e0135439. PubMed ID: 26407177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
